TM9SF3

Across TCGA pan-cancer cohorts, TM9SF3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TM9SF3 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TM9SF3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TM9SF3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where TM9SF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.731	0.416	.001	24	view →
CCRCC	OS	Quartile	All	0.703	0.963	.002	19	view →
LUAD	DFS	Tertile	II,III,IV	0.266	0.783	.004	13	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TM9SF3–PDAC (OS)

Open the PDAC breakdown →